Nicotine metabolism primarily takes area within the liver. Thus, when nicotine is administered through the GI technique, it undergoes initially-pass metabolism via the liver, bringing about a bioavailability of only about 20%. This process inherently decreases the bioavailability of nicotine in the technique and may lead to adverse GI consequences.